Anti proliferative and apoptotic effects on pancreatic cancer cell lines indicate new roles for ANGPTL8 (Betatrophin)
Despite considerable advances, the treatment of pancreatic cancer (PC) still requires much effort. Unusual regulation of the Wnt and apoptotic signaling pathways is widespread in cancer incidence. For instance, the WIF1 (Wnt inhibitory factor 1) gene is down-regulated in many cancers. The purpose of...
Gespeichert in:
Veröffentlicht in: | Genetics and molecular biology 2020-01, Vol.43 (3), p.e20190196-e20190196 |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Despite considerable advances, the treatment of pancreatic cancer (PC) still
requires much effort. Unusual regulation of the Wnt and apoptotic signaling
pathways is widespread in cancer incidence. For instance, the
WIF1
(Wnt inhibitory factor 1) gene is down-regulated in
many cancers. The purpose of this study was to determine the effects of
recombinant Betatrophin, a recently discovered hormone, on MiaPaca-II and
Panc-1
pancreatic cell lines. Various concentrations of
Betatrophin were added to MiaPaca-II and
Panc-1
pancreatic cell
lines during periods of 24 , 48, and 72 h. The MTT assay was applied to
investigate cell proliferation after treatment. The rate of apoptotic cells was
assessed using double-staining flow cytometry, and the expression levels of the
WIF1
gene and Bcl2 protein was observed by real-time PCR
and western blotting, respectively. The findings of this study suggest that
Betatrophin has an anti-proliferative effect on both MiaPaca-II and Panc-1 cell
lines, in line with the up-regulation of
WIF1
as a tumor
suppressor gene. Moreover, the induction of apoptosis by ANGPTL8 occurred by the
down-regulation of Bcl2. Thus, Betatrophin can be proposed as a potential
therapeutic drug for treating pancreatic cancer. |
---|---|
ISSN: | 1415-4757 1678-4685 1678-4685 |
DOI: | 10.1590/1678-4685-gmb-2019-0196 |